The bill is poised to positively affect the treatment landscape for opioid overdoses in Hawaii by ensuring that individuals covered under a variety of health insurance plans—including individual, group, and health maintenance organization policies—will have access to opioid antagonists without significant financial barriers. Importantly, these medications will be placed on the lowest cost-sharing tier of insurance formularies and will not be subject to annual or lifetime dollar limits, reflecting a commitment to prioritize addiction treatment and recovery efforts.
Summary
House Bill 1767 introduces significant amendments to existing health insurance laws in Hawaii concerning opioid antagonists, specifically mandating that all health insurance policies provide coverage for at least one generic form of an opioid antagonist, such as naloxone. Effective from January 1, 2027, this requirement is aimed at enhancing access to lifesaving medications used in the treatment of opioid overdoses, addressing the ongoing opioid crisis by encouraging broader distribution and use of these medications across the state.
Contention
While the bill is likely to have broad support among health advocates and some lawmakers, potential points of contention may arise regarding the implementation of such coverage requirements among insurers and healthcare providers. Concerns may center around the financial implications for health insurers, especially with respect to how the mandates could affect premiums and overall healthcare costs. Additionally, certain stakeholders may debate the effectiveness of such measures in mitigating the opioid crisis, particularly if access to treatment is not paired with supportive services or education on overdose prevention.
Relating to measures to prevent and respond to opioid-related drug overdoses, including policies and training regarding the use of opioid antagonists, at student residences on campuses of public institutions of higher education; providing immunity.
Relating to measures to prevent and respond to opioid-related drug overdoses, including policies and training regarding the use of opioid antagonists, at student residences on campuses of public institutions of higher education; providing immunity.
Exempting law enforcement agencies who do not provide emergency opioid antagonistspursuant to the statewide protocol from the requirement to procure a physician medical director.